


## Piperacillin-Tazobactam Extended Infusion Education

The efficacy of antibiotics can be predicted by pharmacokinetic-pharmacodynamic (PK-PD) parameters such as:

- **T>MIC:** the amount of time (T) serum concentration exceeds the minimum inhibitory concentrations (MIC) of an antibiotic against a strain of bacteria during a dosing interval. Antibiotics such as  $\beta$ -lactams (penicillins, cephalosporins, carbapenems) fall into this category.
- **$C_{max}/MIC$ :** the ratio of maximum serum concentration ( $C_{max}$ ) of an antibiotic to MIC. Efficacy of aminoglycosides can be predicted based on this ratio.
- **AUC/MIC:** the ratio of area under the concentration-time curve (AUC) to MIC. Efficacy of vancomycin, fluoroquinolones, and macrolides can be predicted based on this ratio.




**Figure 1.** PK-PD parameters for prediction of antibiotic efficacy<sup>1</sup>

**Table 1.** Representative PK-PD category, target values that predict efficacy for selected antibiotic-pathogen combinations<sup>1-3</sup>


PK-PD Parameter Predictor	Antibiotic-Pathogen Combination	Target Value
<b>T&gt;MIC</b>	Penicillins--Gram positive organisms	30 – 40%
	Penicillins--Gram negative organisms	50 – 60%
	Cephalosporins—Gram positive organisms	40 – 50%
	Cephalosporins—Gram negative organisms	60 – 70%
	Carbapenems—Gram positive organisms	20 – 30%
	Carbapenems—Gram negative organisms	40 – 50%
<b><math>C_{max}/MIC</math></b>	Aminoglycosides—Gram negative organisms	$\geq 10$
<b>AUC/MIC</b>	Vancomycin— <i>Staphylococcus aureus</i> (in pneumonia)	$\geq 400$
	Ciprofloxacin—Gram negative organisms (in pneumonia)	$\geq 125$
	Levofloxacin—Gram negative organisms (in pneumonia)	$\geq 87$

Traditionally,  $\beta$ -lactams, including piperacillin-tazobactam, are administered using short infusions over 30 to 60 minutes. With better understanding of antibiotic PK-PD,  $\beta$ -lactams are being administered over longer duration of 3-4 hours. The rationale of this practice is to maximize T>MIC, allowing a given dosing regimen to target pathogen with higher MIC. Figure 2 illustrates an example in which both short and extended infusions of a penicillin was able to reach the T>MIC target of 50-60% for Gram negative bacilli (GNB) 2. However, with a higher MIC, only the extended infusion regimen was able to reach that target for GNB 1.



**Figure 2.** Differences in serum concentration relative to MIC with short and extended antibiotic infusions

Monte Carlo simulation, a predictive analytical technique, has been used to predict the efficacy of antibiotic regimens with different doses, frequencies and administration times against pathogens with different MICs. In one particular study, Lodise, *et al.* predicted that a dosing regimen of piperacillin-tazobactam 3.375g q8h infused over 4 hours has a higher probability of reaching the T>MIC target of 50% against *Pseudomonas aeruginosa* isolates with MIC of 16 mcg/mL (the current susceptibility breakpoint) compared to a regimen of 3.375g q6h infused over 0.5 hour (0% vs. ~90%).<sup>4</sup>



**Figure 3.** Probability of reaching the target of T>MIC 50% (or target attainment) using different piperacillin-tazobactam regimens against *P aeruginosa* with different MIC.

A retrospective cohort study comparing the clinical outcomes of patients with *P aeruginosa* infections treated with short (0.5-hour) or extended (4-hour) infusions of piperacillin-tazobactam found improved outcomes with the latter administration strategy.<sup>5</sup> For patients with APACHE score  $\geq 17$ , lower 14-day mortality (12.2% vs. 31.6%,  $p=0.04$ ) and shorter median length of stay (21 vs. 38 days,  $p=0.02$ ) were associated with the extended infusion regimen. These clinical outcomes, however, were similar between different infusion regimens for patients with APACHE score  $< 17$ . A meta-analysis that included 6 studies also found lower mortality risk with extended infusion of piperacillin-tazobactam compared to the short infusion (risk ratio 0.55, 95% CI 0.34-0.89) strategy.<sup>6</sup>

Taken together, these data suggest that the use of extended infusion of piperacillin-tazobactam is associated with shorter hospital stay and/or lower mortality.

### Extended Infusion Piperacillin-Tazobactam Dosing Regimen for Adults

Creatinine Clearance (mL/min)	Dosing Regimen*
$\geq 20$	4.5g IV q8h infused over 4 hours
$< 20$ , HD, or CAPD	4.5g IV q12h infused over 4 hours

Abbreviations: HD = hemodialysis; CAPD = continuous ambulatory peritoneal dialysis

\* A loading dose of 4.5g infused over 30 minutes can be given

### References

- Asin-Prieto E, Rodriguez-Gascon A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. *J Infect Chemother* 2015;21:319-29.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998;26:1-12.
- Ambrose PG, Bhavnani SM, Rubino CM, *et al.* Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. *Clin Infect Dis* 2007;44:79-86.
- Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on  $\beta$ -lactam antibiotics. *Pharmacotherapy* 2006;26:1320-32.
- Lodise TP, Lomaestro, Drusano. Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infection Dis* 2007;44:357-63.
- Falagas ME, Tansarli GS, Ikawa K, *et al.* Clinical outcomes with extended or continuous versus short term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. *Clin Infect Dis* 2013;56:272-82.